Completed PHASE2 INTERVENTIONAL 1-arm NCT01466231

Everolimus in Refractory Testicular Germ Cell Cancer

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

Sponsor: National Cancer Institute, Slovakia

Interventions Everolimus

Updated 5 times since 2017 Last updated: Jan 11, 2016 Started: Nov 30, 2011 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01466231, this PHASE2 trial focuses on Germ Cell Tumor and remains completed. Sponsored by National Cancer Institute, Slovakia, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute, Slovakia

Data source: National Cancer Institute, Slovakia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bratislava, Slovakia